NCT07129759View on ClinicalTrials.gov

Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

September 30, 2026

Primary Completion Date

February 28, 2030

Study Completion Date

February 28, 2030

Conditions

Growth Hormone Deficiency (GHD)

Interventions

DRUG

LUM-201

1.6 mg/kg/day, administered orally once daily

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Lumos Pharma

INDUSTRY